Kymera Therapeutics presented Phase 1 clinical trial results for KT-621, a novel oral STAT6 degrader, in healthy Japanese adults at the Japanese Dermatological Association meeting. The study showed KT-621 was well tolerated, with rapid and sustained STAT6 degradation and favorable pharmacokinetics, consistent with prior studies in non-Japanese subjects. KT-621 targets chronic Type 2 inflammatory diseases like atopic dermatitis and asthma, with ongoing Phase 2b trials expected to report data by mid-2027 and late 2027. These results support KT-621's potential as a new oral treatment option for multiple inflammatory conditions globally.
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
